Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 6/20 | 0.48 |
| ▸ | ESR2 | Q92731 | 6/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 5/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.38 |
| ▸ | HTT | P42858 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | ABHD6 | Q9BV23 | 3/20 | 0.34 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5780558 | 0.91 | ESR1 (0.43) | ESR1ESR2L3MBTL1MEN1KMT2A | |
| SCHEMBL5874074 | 0.85 | ESR1 (0.48) | ESR1ESR2L3MBTL1MEN1KMT2A | |
| SCHEMBL13076095 | 0.85 | ESR1 (0.45) | ESR1ESR2L3MBTL1MEN1KMT2A | |
| SCHEMBL14788111 | 0.84 | BAZ2B (0.47) | L3MBTL1MEN1KMT2AHTTLMNA | |
| SCHEMBL25307344 | 0.81 | ESR2 (0.52) | ESR2L3MBTL1MEN1KMT2AHTT | |
| SCHEMBL31034811 | 0.81 | ESR2 (0.52) | ESR2L3MBTL1MEN1KMT2AHTT | |
| SCHEMBL13645825 | 0.80 | ESR1 (0.52) | ESR1ESR2PKMABHD6 | |
| SCHEMBL8191445 | 0.80 | ESR1 (0.52) | ESR1ESR2PKMABHD6 | |
| SCHEMBL114156 | 0.79 | ESR1 (0.65) | ESR1ESR2MEN1KMT2AHTT | |
| SCHEMBL29805828 | 0.79 | ESR1 (0.65) | ESR1ESR2MEN1KMT2AHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2424532-B1 | COMPOUNDS FOR INDUCING CELLULAR APOPTOSIS | QUEEN MARY & WESTFIELD COLLEGE (GB) | 2014-09-24 | — | — | EP | disclosed |
| EP-2424532-B1 | COMPOUNDS FOR INDUCING CELLULAR APOPTOSIS | QUEEN MARY & WESTFIELD COLLEGE (GB) | 2014-09-24 | — | — | EP | disclosed |
| US-8716302-B2 | Compounds for inducing cellular apoptosis | QUEEN MARY & WESTFIELD COLLEGE (GB) | 2014-05-06 | — | — | US | disclosed |
| US-8716302-B2 | Compounds for inducing cellular apoptosis | QUEEN MARY & WESTFIELD COLLEGE (GB) | 2014-05-06 | — | — | US | disclosed |
| US-8716302-B2 | Compounds for inducing cellular apoptosis | QUEEN MARY & WESTFIELD COLLEGE (GB) | 2014-05-06 | — | — | US | disclosed |
| US-20130072473-A1 | COMPOUNDS FOR TREATING PROTEIN FOLDING DISORDERS | PROTEOSTASIS THERAPEUTICS, INC. | 2013-03-21 | — | — | US | disclosed |
| US-20130072473-A1 | COMPOUNDS FOR TREATING PROTEIN FOLDING DISORDERS | PROTEOSTASIS THERAPEUTICS, INC. | 2013-03-21 | — | — | US | disclosed |
| WO-2012154888-A1 | COMPOUNDS FOR TREATING PROTEIN FOLDING DISORDERS | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2012-11-15 | — | — | WO | disclosed |
| WO-2012154888-A1 | COMPOUNDS FOR TREATING PROTEIN FOLDING DISORDERS | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2012-11-15 | — | — | WO | disclosed |
| US-20120101115-A1 | Compounds For Inducing Cellular Apoptosis | QUEEN MARY AND WESTFIELD COLLEGE (GB) | 2012-04-26 | — | — | US | disclosed |
| EP-1367055-B1 | Isoquinolinyl carboxamides and their use as anticonvulsants | SMITHKLINE BEECHAM PLC (GB) | 2005-10-19 | — | — | EP | disclosed |
| US-6770657-B2 | ARYL OR HETEROARYL-SUBSTITUTED TETRAHYDROISOQUINOLINE DERIVATES POSSESS ANTI-CONVULSANT ACTIVITY AND ARE THEREFORE BELIEVED TO BE USEFUL IN THE TREATMENT AND/OR PREVENTION OF MANY DISEASES | SMITHKLINE BEECHAM P.L.C. (GB) | 2004-08-03 | — | — | US | disclosed |
| US-20040142964-A1 | Novel compounds | SMITHKLINE BEECHAM P.L.C. | 2004-07-22 | — | — | US | disclosed |
| EP-1200409-B1 | SUBSTITUTED ISOQUINOLINE DERIVATIVES AND THEIR USE AS ANTICONVULSANTS | SMITHKLINE BEECHAM PLC (GB) | 2004-02-25 | — | — | EP | disclosed |
| EP-1367055-A1 | Isoquinolinyl carboxamides and their use as anticonvulsants | SMITHKLINE BEECHAM PLC (GB) | 2003-12-03 | — | — | EP | disclosed |
| US-20030036551-A1 | Novel compounds | SMITHKLINE BEECHAM P.L.C. | 2003-02-20 | — | — | US | disclosed |
| US-6492388-B1 | SUCH AS N-(5-CHLORO-1,2,3,4-TETRAHYDROISOQUINOLIN-7-YL)-4-ETHOXYBENZAMIDE | SMITHKLINE BEECHAM P.L.C. (GB) | 2002-12-10 | — | — | US | disclosed |
| EP-1200409-A2 | SUBSTITUTED ISOQUINOLINE DERIVATIVES AND THEIR USE AS ANTICONVULSANTS | SMITHKLINE BEECHAM PLC (GB) | 2002-05-02 | — | — | EP | disclosed |
| WO-2001002366-A2 | SUBSTITUTED ISOQUINOLINE DERIVATIVES AND THEIR USE AS INTICONVULSANTS | SMITHKLINE BEECHAM P.L.C. (GB) | 2001-01-11 | — | — | WO | disclosed |
| WO-2000007993-A1 | SUBSTITUTED ISOQUINOLEINES AND THEIR USE AS ANTICONVULSIVANTS | SMITHKLINE BEECHAM PLC (GB) | 2000-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130072473-A1 | COMPOUNDS FOR TREATING PROTEIN FOLDING DISORDERS | HSPA5, PSMG3, VCP | ESR1 4113/4885ESR2 3581/4885L3MBTL1 1376/4885 |
| US-20120101115-A1 | Compounds For Inducing Cellular Apoptosis | BAD, BAX, CASP3 | ESR1 3474/4885ESR2 2946/4885L3MBTL1 810/4885 |
| US-20030036551-A1 | Novel compounds | SCN1B, CNR1, SCN1A | ESR1 1965/4885ESR2 843/4885L3MBTL1 1997/4885 |
| US-20040142964-A1 | Novel compounds | GRIN2C, GRIN2A, NLN | ESR1 3977/4885ESR2 2797/4885L3MBTL1 3414/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.